0001554795-21-000187.txt : 20210517 0001554795-21-000187.hdr.sgml : 20210517 20210517151452 ACCESSION NUMBER: 0001554795-21-000187 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 28 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210517 DATE AS OF CHANGE: 20210517 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CANCER CAPITAL CORP CENTRAL INDEX KEY: 0001130889 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 911803648 STATE OF INCORPORATION: WY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-32363 FILM NUMBER: 21929777 BUSINESS ADDRESS: STREET 1: 2157 S. LINCOLN STREET 2: SUITE 200 CITY: SALT LAKE CITY STATE: UT ZIP: 84106 BUSINESS PHONE: 801-323-2395 MAIL ADDRESS: STREET 1: 2157 S. LINCOLN STREET 2: SUITE 200 CITY: SALT LAKE CITY STATE: UT ZIP: 84106 10-Q 1 cncl0514form10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2021

 

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ___ to ___

 

Commission file number: 000-32363

 

CANCER CAPITAL CORP.

(Exact name of registrant as specified in its charter)

Wyoming

(State or other jurisdiction of incorporation or organization)

91-1803648

(I.R.S. Employer Identification No.)

2157 S. Lincoln Street, Suite 200, Salt Lake City, Utah

(Address of principal executive offices)

84106

(Zip code)

(801) 323-2395

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐

 

Non-accelerated filer ☑

Accelerated filer ☐

Smaller reporting company ☑

Emerging growth company ☑

  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☑ No ☐

 

The number of shares outstanding of the registrant’s common stock as of May 17, 2021 was 6,150,000.

 

 
 

TABLE OF CONTENTS

 

  PART I – FINANCIAL INFORMATION  
     
Item 1. Financial Statements (Unaudited) 3
Condensed Balance Sheets (Unaudited) 4
  Condensed Statements of Operations (Unaudited) 5
  Condensed Statements of Stockholders’ Deficit (Unaudited) 6
  Condensed Statements of Cash Flows (Unaudited) 7
  Condensed Notes to the Unaudited Financial Statements 8
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 9
Item 3. Quantitative and Qualitative Disclosures about Market Risk 11
Item 4. Controls and Procedures 11
     
  PART II – OTHER INFORMATION  
     
Item 1. Legal Proceedings 12
Item 1a. Risk Factors Information 12
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 12
Item 3. Defaults Upon Senior Securities 12
Item 4. Mine Safety Disclosures 12
Item 5. Other Information 12
Item 6. Exhibits 12
Signatures 13

 

 

 

 

PART I – FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

 

 

CANCER CAPITAL CORP.

 

Condensed Financial Statements

 

March 31, 2021

 

(Unaudited) 

 

 3 

 

Cancer Capital Corp.

Condensed Balance Sheets

(Unaudited)

       
   MAR 31, 2021  DEC 31, 2020
ASSETS          
CURRENT ASSETS          
Cash  $698   $698 
Total current assets   698    698 
Total assets  $698   $698 
           
LIABILITIES AND STOCKHOLDERS' DEFICIT          
CURRENT LIABILITIES          
Accounts payable – related party  $7,500   $6,000 
Accounts payable   3,900    —   
Notes payable – related party   139,125    139,125 
Notes payable   85,575    85,575 
Accrued interest – related party   57,602    54,819 
Accrued interest   49,230    47,519 
Total current liabilities   342,932    333,038 
Total liabilities   342,932    333,038 
           
STOCKHOLDERS' DEFICIT          
Common stock, $.001 par value; 20,000,000 shares
authorized; 6,150,000 shares issued and outstanding		   6,150    6,150 
Additional paid-in capital   47,050    47,050 
Accumulated deficit   (395,434)   (385,540)
Total stockholders' deficit   (342,234)   (332,340)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT  $698   $698 

 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

 4 

 

Cancer Capital Corp.

Condensed Statements of Operations

(Unaudited)

 

   FOR THE
THREE MONTHS ENDED
MAR 31, 2021		  FOR THE
THREE MONTHS
ENDED
MAR 31, 2020
Revenues  $—     $—   
       
Operating expenses          
General and administrative   5,400    5,415 
Total operating expenses   5,400    5,415 
           
Loss from operations   (5,400)   (5,415)
           
Other expense non-operating          
Interest expense – related party   (2,783)   (2,541)
Interest expense   (1,711)   (1,651)
Total other expense   (4,494)   (4,192)
           
Loss before income taxes   (9,894)   (9,607)
           
Income tax expense   —      —   
           
Net loss  $(9,894)  $(9,607)
           
Net loss per share – Basic and diluted  $(0.00)  $(0.00)
           
Weighted average shares outstanding - Basic and diluted   6,150,000    6,150,000 

 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 5 

 

Cancer Capital Corp.

Condensed Statements of Stockholders’ Deficit

For the three months ended March 31, 2021 and 2020

(Unaudited)

             
   Common Stock  Additional
Paid-in		  Accumulated  Total
Stockholders’
   Shares  Amount  Capital  Deficit  Deficit
Balance – December 31, 2019   6,150,000   $6,150   $47,050   $(354,786)  $(301,586)
Net income (loss) for the quarter ended – March 31, 2020        —      —      (9,607)   (9,607)
Balance – March 31, 2020   6,150,000   $6,150   $47,050   $(364,393)  $(311,193)
                          
                          
Balance – December 31, 2020   6,150,000   $6,150   $47,050   $(385,540)  $(332,340)
Net income (loss) for the quarter ended – March 31, 2021   —      —      —      (9,894)   (9,894)
Balance – March 31, 2021   6,150,000   $6,150   $47,050   $(395,434)  $(342,234)

 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 6 

 

Cancer Capital Corp.

Condensed Statements of Cash Flows

(Unaudited)

       
   FOR THE
THREE MONTHS ENDED
MAR 31, 2021		  FOR THE
THREE MONTHS ENDED
MAR 31, 2020
Cash Flows from Operating Activities          
Net Loss  $(9,894)  $(9,607)
Adjustment to reconcile net loss to cash used by
operating activities:		          
Expenses paid by related party   1,500    1,500 
Changes in operating assets and liabilities:          
Increase in accounts payable   3,900    1,200 
Increase in accrued interest – related party   2,783    2,541 
Increase in accrued interest   1,711    1,651 
Net cash used by operating activities   —      (2,715)
           
Cash Flows from Investing Activities          
Net cash provided by investing activities   —      —   
           
Cash Flows from Financing Activities          
Proceeds from notes payable   —      6,200 
Net cash provided by financing activities   —      6,200 
           
Increase (decrease) in cash   —      3,485 
           
Cash and cash equivalents at beginning of period   698    218 
           
Cash and cash equivalents at end of period  $698   $3,703 
           
Supplemental Cash Flow Information:          
Cash paid for interest  $—     $—   
Cash paid for income taxes  $—     $—   

 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 7 

 

Cancer Capital Corp.

Notes to the Condensed Financial Statements

(Unaudited)

March 31, 2021

 

NOTE 1 – CONDENSED FINANCIAL STATEMENT

 

The accompanying unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted in accordance with such rules and regulations. The information furnished in the interim condensed financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements. Although management believes the disclosures and information presented are adequate to make the information not misleading, it is suggested that these interim condensed financial statements be read in conjunction with the Company’s audited financial statements and notes thereto included in its December 31, 2020 Annual Report on Form 10-K. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for year ending December 31, 2021.

 

NOTE 2 – GOING CONCERN

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has limited assets, has incurred losses since inception, has negative cash flows from operations, and has no revenue-generating activities. Its activities have been limited for the past several years and it is dependent upon financing to continue operations. These factors raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. It is management’s plan to acquire or merge with other operating companies.

 

NOTE 3 – RELATED PARTY TRANSACTIONS

 

During the three months ended March 31, 2021, a shareholder invoiced the Company for consulting, administrative and professional services and out-of-pocket costs provided or paid on behalf of the Company totaling $1,500, resulting in the Company owing the shareholder $7,500 and $6,000 at March 31, 2021 and December 31, 2020, respectively.

 

During the three months ended March 31, 2021 and 2020, a shareholder loaned the Company $0 and $0, respectively. The notes bear interest at 8% and are due on demand. Notes payable – related party at March 31, 2021 and December 31, 2020 were $139,125 and $139,125, respectively. Accrued interest at March 31, 2021 and December 31, 2020 was $57,602 and $54,819, respectively.

 

NOTE 4 – NOTES PAYABLE

 

During the three months ended March 31, 2021 and 2020, the Company was loaned $0 and $6,200, respectively. The notes bear interest at 8% and are due on demand. Notes payable at March 31, 2021 and December 31, 2020 were $85,575 and $85,575, respectively. Accrued interest at March 31, 2021 and December 31, 2020 was $49,230 and $47,519, respectively.

 

NOTE 5 – SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and has determined that there are no such events that would have a material impact on the financial statements.

 

 8 

 

 

FORWARD LOOKING STATEMENTS

 

The Securities and Exchange Commission (“SEC”) encourages companies to disclose forward-looking information so that investors can better understand future prospects and make informed investment decisions. This report contains these types of statements. Words such as “may,” “intend,” “expect,” “believe,” “anticipate,” “estimate,” “project,” or “continue” or comparable terminology used in connection with any discussion of future operating results or financial performance identify forward-looking statements. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this report. All forward-looking statements reflect our present expectation of future events and are subject to a number of important factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

 

In this report references to “Cancer Capital,” “the Company,” “we,” “us,” and “our” refer to Cancer Capital Corp.

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Executive Overview

 

We have not recorded revenues since inception and we are dependent upon financing to continue basic operations. Management intends to rely upon advances or loans from management, significant stockholders or third parties to meet our cash requirements, but we have not entered into written agreements guaranteeing funds and, therefore, no one is obligated to provide funds to us in the future. These factors raise substantial doubt as to our ability to continue as a going concern. Our plan is to combine with an operating company to generate revenue. At this time management is unsure what effect the COVID-19 pandemic will have on our search for companies to combine with.

 

As of the date of this report, our management has not had any discussions with any representative of any other entity regarding a business combination with us. Any target business that is selected may be a financially unstable company or an entity in its early stages of development or growth, including entities without established records of sales or earnings. In that event, we will be subject to numerous risks inherent in the business and operations of financially unstable and early stage or potential emerging growth companies. In addition, we may complete a business combination with an entity in an industry characterized by a high level of risk, and, although our management will endeavor to evaluate the risks inherent in a particular target business, there can be no assurance that we will properly ascertain or assess all significant risks. In addition, any business combination or transaction will likely result in a significant issuance of shares and substantial dilution to present stockholders of the Company.

 

We anticipate that the selection of a business opportunity will be complex and extremely risky. Because of general economic conditions, rapid technological advances being made in some industries and shortages of available capital, our management believes that there are numerous firms seeking the perceived benefits of becoming a publicly traded corporation. Such perceived benefits of becoming a publicly traded corporation include, among other things, facilitating or improving the terms on which additional equity financing may be obtained, providing liquidity for the principals of and investors in a business, creating a means for providing incentive stock options or similar benefits to key employees, and offering greater flexibility in structuring acquisitions, joint ventures and the like through the issuance of securities. Potentially available business combinations may occur in many different industries and at various stages of development, all of which will make the task of comparative investigation and analysis of such business opportunities extremely difficult and complex.

 

If we obtain a business opportunity, then it may be necessary to raise additional capital. We anticipate that we will sell our common stock to raise this additional capital. We expect that we would issue such stock pursuant to exemptions to the registration requirements provided by federal and state securities laws. The purchasers and manner of issuance will be determined according to our financial needs and the available exemptions to the registration requirements of the Securities Act of 1933. We do not currently intend to make a public offering of our stock. We also note that if we issue more shares of our common stock, then our stockholders may experience dilution in the value per share of their common stock.

 

 9 

 

Liquidity and Capital Resources

 

We have not recorded revenues from operations since inception and we have not established an ongoing source of revenue sufficient to cover our operating costs. We have relied primarily upon related parties to provide and pay for professional and operational expenses. At March 31, 2021 and December 31, 2020, we had $698 cash and at March 31, 2021, total liabilities increased to $342,932 compared to $333,038 at December 31, 2020.

 

This increase in total liabilities primarily represents an increase in accounts payable and accrued interest for all notes payable and notes payable-related party for cash advances, consulting services and professional services provided by or paid for by a stockholder (See “Commitments and Obligations,” below).

 

We intend to obtain capital from management, significant stockholders and/or third parties to cover minimal operations; however, there is no assurance that additional funding will be available. Our ability to continue as a going concern during the long term is dependent upon our ability to find a suitable business opportunity and acquire or enter into a merger with such company. The type of business opportunity with which we acquire or merge will affect our profitability for the long term.

 

During the next 12 months we anticipate incurring additional costs related to the filing of Exchange Act reports. We believe we will be able to meet these costs through funds provided by management, significant stockholders and/or third parties. We may also rely on the issuance of our common stock in lieu of cash to convert debt or pay for expenses.

 

Results of Operations

 

We did not record revenues in either 2021 or 2020. We did not record a significant change in general and administrative expense for the three months ended March 31, 2021 (“2021 first quarter”) compared to the three months ended March 31, 2020 (“2020 first quarter”)

 

Total other expense increased 7.2% for the 2021 first quarter compared to the 2020 first quarter. Total other expense represents interest expense related to notes payable and notes payable-related party.

 

Our net loss increased 2.9% for the 2021 first quarter compared to the 2020 first quarter. Management expects net losses to continue until we acquire or merge with a business opportunity.

 

Commitments and Obligations

 

At March 31, 2021, we reported notes payable totaling $85,575 with accrued interest of $49,230 and notes payable-related party totaled $139,125 with accrued interest of $57,602. All of the notes payable are non-collateralized, carry interest at 8% and are due on demand.

 

During the 2021 first quarter, a shareholder invoiced the Company for consulting, administrative and professional services and out-of-pocket costs provided or paid on behalf of the Company totaling $1,500, resulting in the Company owing the shareholder $7,500 at March 31, 2021.

 

At March 31, 2021 the Company owed vendors $3,900.

 

As of March 31, 2021, two lenders represent in excess of 95% of our accounts and notes payable.

 

Off-Balance Sheet Arrangements

 

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.

 

Emerging Growth Company

 

We qualify as an emerging growth company as that term is used in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). A company qualifies as an emerging growth company if it has total annual gross revenues of less than $1.07 billion during its most recently completed fiscal year and, as of December 8, 2011, had not sold common equity securities under a registration statement. Under the JOBS Act we are permitted to, and intend to, rely on exemptions from certain disclosure requirements

 

In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards.

 

 10 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable to smaller reporting companies.

 

 

ITEM 4. CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported within the periods specified in the rules and forms of the SEC. This information is accumulated to allow our management to make timely decisions regarding required disclosure. Our President, who serves as our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report and he determined that our disclosure controls and procedures were not effective due to a control deficiency. During the period we did not have additional personnel to allow segregation of duties to ensure the completeness or accuracy of our information. Due to the size and operations of the Company we are unable to remediate this deficiency until we acquire or merge with another company.

 

Changes to Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Management conducted an evaluation of our internal control over financial reporting and determined that there were no changes made in our internal control over financial reporting during the quarter ended March 31, 2021 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

 

 11 

 

PART II – OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

We know of no material, existing or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our company.

 

 

ITEM 1A.  RISK FACTORS

 

As a smaller reporting company, we are not required to provide the information required by this Item.

 

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

 

ITEM 5. OTHER INFORMATION

 

None.

 

 

ITEM 6. EXHIBITS

 

Part I Exhibits

No. Description
31.1 Principal Executive Officer Certification
31.2 Principal Financial Officer Certification
32.1 Section 1350 Certification

 

Part II Exhibits

No.    Description
3(i).1

Articles of Incorporation, dated April 11, 1997 (Incorporated by reference to exhibit 3.1 of the Form 10-SB, File No. 000-32363, filed February 20, 2001)

3(i).2

Wyoming Articles of Domestication for Cancer Capital, dated April 28, 2016 (Incorporated by reference to exhibit 3(i) to Form 10-Q, filed May 13, 2016)

3(ii)

Bylaws of Cancer Capital, dated May 2, 2016 (Incorporated by reference to exhibit 3(ii) to Form 10-Q, filed May 13, 2016)

101.INS XBRL Instance Document
101.SCH XBRL Taxonomy Extension Schema Document
101.CAL XBRL Taxonomy Calculation Linkbase Document
101.CAL XBRL Taxonomy Extension Definition Linkbase Document
101.LAB XBRL Taxonomy Label Linkbase Document
101.PRE XBRL Taxonomy Presentation Linkbase Document

 

 12 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Date: May 17, 2021

CANCER CAPITAL CORP.

 

By:  /s/ John W. Peters

John W. Peters

President and Director

Principal Financial Officer

 

 

13

 EX-31.1 2 cncl0514form10qexh31_1.htm EXHIBIT 31.1

Exhibit 31.1

 

PRINCIPAL EXECUTIVE OFFICER CERTIFICATION

 

I, John W. Peters, certify that:

 

1.I have reviewed this quarterly report on Form 10-Q of Cancer Capital Corp.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statement made, in light of the circumstances under which statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Date: May 17, 2021

 

/s/ John W. Peters

John W. Peters

Principal Executive Officer

 EX-31.2 3 cncl0514form10qexh31_2.htm EXHIBIT 31.2

Exhibit 31.2

 

PRINCIPAL FINANCIAL OFFICER CERTIFICATION

 

I, John W. Peters, certify that:

 

1.I have reviewed this quarterly report on Form 10-Q of Cancer Capital Corp.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statement made, in light of the circumstances under which statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Date: May 17, 2021

 

/s/ John W. Peters

John W. Peters

Principal Financial Officer

 EX-32.1 4 cncl0514form10qexh32_1.htm EXHIBIT 32.1

Exhibit 32.1

 

CANCER CAPITAL CORP.

 

CERTIFICATION OF PERIODIC REPORT

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

18 U.S.C. Section 1350

 

The undersigned executive officer of Cancer Capital Corp. certifies pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that:

 

a.the quarterly report on Form 10-Q of Cancer Capital Corp. for the quarter ended March 31, 2021, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

b.the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Cancer Capital Corp.

 

 

 

Date: May 17, 2021

 

 

/s/ John W. Peters

John W. Peters

Principal Executive Officer

Principal Financial Officer

 EX-101.INS 5 cncl-20210331.xml XBRL INSTANCE FILE 0001130889 2021-01-01 2021-03-31 0001130889 2021-05-17 0001130889 2021-03-31 0001130889 2020-12-31 0001130889 2020-01-01 2020-03-31 0001130889 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001130889 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001130889 us-gaap:CommonStockMember 2020-12-31 0001130889 us-gaap:CommonStockMember 2021-03-31 0001130889 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001130889 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001130889 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001130889 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001130889 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001130889 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001130889 us-gaap:RetainedEarningsMember 2021-03-31 0001130889 us-gaap:CommonStockMember 2020-03-31 0001130889 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001130889 us-gaap:RetainedEarningsMember 2020-03-31 0001130889 2020-03-31 0001130889 2019-12-31 0001130889 us-gaap:CommonStockMember 2019-12-31 0001130889 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001130889 us-gaap:RetainedEarningsMember 2019-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure <p style="font: 11pt Times New Roman, Times, Serif; margin: 0">NOTE 5 &#8211; SUBSEQUENT EVENTS</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 11pt/13.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and has determined that there are no such events that would have a material impact on the financial statements.</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0">NOTE 2 &#8211; GOING CONCERN</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has limited assets, has incurred losses since inception, has negative cash flows from operations, and has no revenue-generating activities. Its activities have been limited for the past several years and it is dependent upon financing to continue operations. These factors raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. It is management&#8217;s plan to acquire or merge with other operating companies.</p> 0001130889 10-Q 2021-03-31 Yes Yes true true WY --12-31 false false Non-accelerated Filer 6150000 Q1 2021 true <p style="font: 11pt Times New Roman, Times, Serif; margin: 0">NOTE 4 &#8211; NOTES PAYABLE</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended March 31, 2021 and 2020, the Company was loaned $0 and $6,200, respectively. The notes bear interest at 8% and are due on demand. Notes payable at March 31, 2021 and December 31, 2020 were $85,575 and $85,575, respectively. Accrued interest at March 31, 2021 and December 31, 2020 was $49,230 and $47,519, respectively.</p> 0.08 0.08 49230 47519 000-32363 CANCER CAPITAL CORP <p style="font: 11pt Times New Roman, Times, Serif; margin: 0">NOTE 1 &#8211; CONDENSED FINANCIAL STATEMENT</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted in accordance with such rules and regulations. The information furnished in the interim condensed financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements. Although management believes the disclosures and information presented are adequate to make the information not misleading, it is suggested that these interim condensed financial statements be read in conjunction with the Company&#8217;s audited financial statements and notes thereto included in its December 31, 2020 Annual Report on Form 10-K. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for year ending December 31, 2021.</p> 0.001 0.001 20000000 20000000 6150000 6150000 6150000 6150000 698 698 698 698 698 698 3703 218 342932 333038 342932 333038 49230 47519 57602 54819 85575 85575 139125 139125 3900 7500 6000 698 698 -342234 -332340 6150 6150 47050 47050 -395434 6150 47050 -364393 -311193 -301586 6150 47050 -354786 -395434 -385540 47050 47050 6150 6150 5400 5415 5400 5415 -5400 -5415 -4494 -4192 1711 1651 2783 2541 -9894 -9607 -9894 -9607 -9607 -9894 0.00 0.00 6150000 6150000 6150000 6150000 6150000 6150000 -2715 1711 1651 2783 2541 3900 1200 1500 1500 6200 6200 3485 <p style="font: 11pt Times New Roman, Times, Serif; margin: 0">NOTE 3 &#8211; RELATED PARTY TRANSACTIONS</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended March 31, 2021, a shareholder invoiced the Company for consulting, administrative and professional services and out-of-pocket costs provided or paid on behalf of the Company totaling $1,500, resulting in the Company owing the shareholder $7,500 and $6,000 at March 31, 2021 and December 31, 2020, respectively.</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended March 31, 2021 and 2020, a shareholder loaned the Company $0 and $0, respectively. The notes bear interest at 8% and are due on demand. Notes payable &#8211; related party at March 31, 2021 and December 31, 2020 were $139,125 and $139,125, respectively. Accrued interest at March 31, 2021 and December 31, 2020 was $57,602 and $54,819, respectively.</p> 1500 7500 6000 57602 54819 6200 EX-101.SCH 6 cncl-20210331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statements of Stockholders’ Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - CONDENSED FINANCIAL STATEMENTS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 cncl-20210331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 cncl-20210331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 cncl-20210331_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock Additional Paid-In Capital Accumulated Deficit Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Entity Incorporation, State or Country Code Amendment Flag Amendment Description Current Fiscal Year End Date Entity File Number Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Interactive Data Current Is Entity Emerging Growth Company? Elected Not To Use the Extended Transition Period Entity Filer Category Entity Small Business Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Entity Shell Company Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash Total current assets Total assets LIABILITIES AND STOCKHOLDERS' DEFICIT CURRENT LIABILITIES Accounts payable - related party Accounts payable Notes payable - related party Notes payable Accrued interest - related party Accrued interest Total current liabilities Total liabilities STOCKHOLDERS' DEFICIT Common stock, $.001 par value; 20,000,000 shares authorized; 6,150,000 shares issued and outstanding Additional paid-in capital Accumulated deficit Total stockholders' deficit TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT Common stock, par value Common stock, authorized Common stock, issued Common stock, outstanding Income Statement [Abstract] Revenues Operating expenses General and administrative Total operating expenses Loss from operations Other expense non-operating Interest expense - related party Interest expense Total other expense Loss before income taxes Income tax expense Net loss Net loss per share – Basic and diluted Weighted average shares outstanding - Basic and diluted Statement [Table] Statement [Line Items] Beginning balance, shares Beginning balance, amount Net income (loss) Ending balance, shares Ending balance, amount Statement of Cash Flows [Abstract] Cash Flows from Operating Activities Net Loss Adjustments to reconcile net loss to cash used by operating activities: Expenses paid by related party Changes in operating assets and liabilities: Increase in accounts payable Increase in accrued interest - related party Increase in accrued interest Net cash used by operating activities Cash Flows from Investing Activities Net cash provided by investing activities Cash Flows from Financing Activities Proceeds from notes payable Net cash provided by financing activities Increase (decrease) in cash Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental Cash Flow Information: Cash paid for interest Cash paid for income taxes Accounting Policies [Abstract] CONDENSED FINANCIAL STATEMENTS Organization, Consolidation and Presentation of Financial Statements [Abstract] GOING CONCERN Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Debt Disclosure [Abstract] NOTES PAYABLE Subsequent Events [Abstract] SUBSEQUENT EVENTS Consulting, administrative and professional costs provided for or paid on behalf of Company by shareholder Due to related party Accrued interest on notes payable - related party Interest rate on notes payable - related party Amounts loaned to Company Interest rate Accrued interest Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense, Related Party Interest Expense Other Operating Income (Expense), Net Income (Loss) from Continuing Operations before Income Taxes, Domestic Increase (Decrease) in Income Taxes Shares, Outstanding Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Accrued Liabilities, Current EX-101.PRE 10 cncl-20210331_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document and Entity Information - shares
 3 Months Ended
Mar. 31, 2021
May 17, 2021
Document And Entity Information    
Entity Registrant Name CANCER CAPITAL CORP  
Entity Central Index Key 0001130889  
Document Type 10-Q  
Document Period End Date Mar. 31, 2021  
Entity Incorporation, State or Country Code WY  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Entity File Number 000-32363  
Is Entity's Reporting Status Current? Yes  
Entity Interactive Data Current Yes  
Is Entity Emerging Growth Company? true  
Elected Not To Use the Extended Transition Period false  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Common Stock, Shares Outstanding   6,150,000
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2021  
Entity Shell Company true  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2021
Dec. 31, 2020
CURRENT ASSETS    
Cash $ 698 $ 698
Total current assets 698 698
Total assets 698 698
CURRENT LIABILITIES    
Accounts payable - related party 7,500 6,000
Accounts payable 3,900
Notes payable - related party 139,125 139,125
Notes payable 85,575 85,575
Accrued interest - related party 57,602 54,819
Accrued interest 49,230 47,519
Total current liabilities 342,932 333,038
Total liabilities 342,932 333,038
STOCKHOLDERS' DEFICIT    
Common stock, $.001 par value; 20,000,000 shares authorized; 6,150,000 shares issued and outstanding 6,150 6,150
Additional paid-in capital 47,050 47,050
Accumulated deficit (395,434) (385,540)
Total stockholders' deficit (342,234) (332,340)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ 698 $ 698
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Common stock, par value $ 0.001 $ 0.001
Common stock, authorized 20,000,000 20,000,000
Common stock, issued 6,150,000 6,150,000
Common stock, outstanding 6,150,000 6,150,000
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Statements of Operations (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Income Statement [Abstract]    
Revenues
Operating expenses    
General and administrative 5,400 5,415
Total operating expenses 5,400 5,415
Loss from operations (5,400) (5,415)
Other expense non-operating    
Interest expense - related party (2,783) (2,541)
Interest expense (1,711) (1,651)
Total other expense (4,494) (4,192)
Loss before income taxes (9,894) (9,607)
Income tax expense
Net loss $ (9,894) $ (9,607)
Net loss per share – Basic and diluted $ 0.00 $ 0.00
Weighted average shares outstanding - Basic and diluted 6,150,000 6,150,000
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Statements of Stockholders’ Deficit (Unaudited) - USD ($)
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total
Beginning balance, shares at Dec. 31, 2019 6,150,000      
Beginning balance, amount at Dec. 31, 2019 $ 6,150 $ 47,050 $ (354,786) $ (301,586)
Net income (loss) (9,607) (9,607)
Ending balance, shares at Mar. 31, 2020 6,150,000      
Ending balance, amount at Mar. 31, 2020 $ 6,150 47,050 (364,393) (311,193)
Beginning balance, shares at Dec. 31, 2020 6,150,000      
Beginning balance, amount at Dec. 31, 2020 $ 6,150 47,050   (332,340)
Net income (loss) (9,894) (9,894)
Ending balance, shares at Mar. 31, 2021 6,150,000      
Ending balance, amount at Mar. 31, 2021 $ 6,150 $ 47,050 $ (395,434) $ (342,234)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Cash Flows from Operating Activities    
Net Loss $ (9,894) $ (9,607)
Adjustments to reconcile net loss to cash used by operating activities:    
Expenses paid by related party 1,500 1,500
Changes in operating assets and liabilities:    
Increase in accounts payable 3,900 1,200
Increase in accrued interest - related party 2,783 2,541
Increase in accrued interest 1,711 1,651
Net cash used by operating activities (2,715)
Cash Flows from Investing Activities    
Net cash provided by investing activities
Cash Flows from Financing Activities    
Proceeds from notes payable 6,200
Net cash provided by financing activities 6,200
Increase (decrease) in cash 3,485
Cash and cash equivalents at beginning of period 698 218
Cash and cash equivalents at end of period 698 3,703
Supplemental Cash Flow Information:    
Cash paid for interest
Cash paid for income taxes
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.21.1
CONDENSED FINANCIAL STATEMENTS
 3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
CONDENSED FINANCIAL STATEMENTS

NOTE 1 – CONDENSED FINANCIAL STATEMENT

 

The accompanying unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted in accordance with such rules and regulations. The information furnished in the interim condensed financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements. Although management believes the disclosures and information presented are adequate to make the information not misleading, it is suggested that these interim condensed financial statements be read in conjunction with the Company’s audited financial statements and notes thereto included in its December 31, 2020 Annual Report on Form 10-K. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for year ending December 31, 2021.
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.21.1
GOING CONCERN
 3 Months Ended
Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
GOING CONCERN

NOTE 2 – GOING CONCERN

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has limited assets, has incurred losses since inception, has negative cash flows from operations, and has no revenue-generating activities. Its activities have been limited for the past several years and it is dependent upon financing to continue operations. These factors raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. It is management’s plan to acquire or merge with other operating companies.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.21.1
RELATED PARTY TRANSACTIONS
 3 Months Ended
Mar. 31, 2021
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 3 – RELATED PARTY TRANSACTIONS

 

During the three months ended March 31, 2021, a shareholder invoiced the Company for consulting, administrative and professional services and out-of-pocket costs provided or paid on behalf of the Company totaling $1,500, resulting in the Company owing the shareholder $7,500 and $6,000 at March 31, 2021 and December 31, 2020, respectively.

 

During the three months ended March 31, 2021 and 2020, a shareholder loaned the Company $0 and $0, respectively. The notes bear interest at 8% and are due on demand. Notes payable – related party at March 31, 2021 and December 31, 2020 were $139,125 and $139,125, respectively. Accrued interest at March 31, 2021 and December 31, 2020 was $57,602 and $54,819, respectively.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.21.1
NOTES PAYABLE
 3 Months Ended
Mar. 31, 2021
Debt Disclosure [Abstract]  
NOTES PAYABLE

NOTE 4 – NOTES PAYABLE

 

During the three months ended March 31, 2021 and 2020, the Company was loaned $0 and $6,200, respectively. The notes bear interest at 8% and are due on demand. Notes payable at March 31, 2021 and December 31, 2020 were $85,575 and $85,575, respectively. Accrued interest at March 31, 2021 and December 31, 2020 was $49,230 and $47,519, respectively.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.21.1
SUBSEQUENT EVENTS
 3 Months Ended
Mar. 31, 2021
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 5 – SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and has determined that there are no such events that would have a material impact on the financial statements.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.21.1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Related Party Transactions [Abstract]      
Consulting, administrative and professional costs provided for or paid on behalf of Company by shareholder $ 1,500    
Due to related party 7,500   $ 6,000
Notes payable - related party 139,125   139,125
Accrued interest on notes payable - related party $ 57,602   $ 54,819
Interest rate on notes payable - related party 8.00% 8.00%  
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.21.1
NOTES PAYABLE (Details Narrative) - USD ($)
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Debt Disclosure [Abstract]      
Amounts loaned to Company $ 6,200  
Notes payable $ 85,575   $ 85,575
Interest rate 8.00% 8.00%  
Accrued interest $ 49,230   $ 47,519
EXCEL 24 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 25 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 26 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 27 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 24 154 1 false 3 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://CNCL/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheets (Unaudited) Sheet http://CNCL/role/BalanceSheets Condensed Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://CNCL/role/BalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://CNCL/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Statements of Stockholders??? Deficit (Unaudited) Sheet http://CNCL/role/StatementsOfStockholdersDeficit Condensed Statements of Stockholders??? Deficit (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://CNCL/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - CONDENSED FINANCIAL STATEMENTS Sheet http://CNCL/role/CondensedFinancialStatements CONDENSED FINANCIAL STATEMENTS Notes 7 false false R8.htm 00000008 - Disclosure - GOING CONCERN Sheet http://CNCL/role/GoingConcern GOING CONCERN Notes 8 false false R9.htm 00000009 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://CNCL/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 9 false false R10.htm 00000010 - Disclosure - NOTES PAYABLE Notes http://CNCL/role/NotesPayable NOTES PAYABLE Notes 10 false false R11.htm 00000011 - Disclosure - SUBSEQUENT EVENTS Sheet http://CNCL/role/SubsequentEvents SUBSEQUENT EVENTS Notes 11 false false R12.htm 00000012 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://CNCL/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://CNCL/role/RelatedPartyTransactions 12 false false R13.htm 00000013 - Disclosure - NOTES PAYABLE (Details Narrative) Notes http://CNCL/role/NotesPayableDetailsNarrative NOTES PAYABLE (Details Narrative) Details http://CNCL/role/NotesPayable 13 false false All Reports Book All Reports cncl-20210331.xml cncl-20210331.xsd cncl-20210331_cal.xml cncl-20210331_def.xml cncl-20210331_lab.xml cncl-20210331_pre.xml http://fasb.org/us-gaap/2021-01-31 http://fasb.org/srt/2021-01-31 http://xbrl.sec.gov/dei/2021 true true ZIP 29 0001554795-21-000187-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001554795-21-000187-xbrl.zip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end